A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder
Phase 2
18–65
29 sites in AL, AR, AZ +10
About this study
This Phase 2 study is focused on people with bi polar ii disorder. The primary outcome being measured is Change from Baseline to Week 6 in the MADRS (Montgomery-Åsberg Depression Rating Scale) total score.
Based on ClinicalTrials.gov records.
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Change from Baseline to Week 6 in the MADRS (Montgomery-Åsberg Depression Rating Scale) total score, Number of Participants with Adverse Events (AEs)
Secondary: Change from Baseline to Week 6 in Clinician Global Impression of Severity - Bipolar Disorder (CGI-S-BP) score
Psychiatry / Mental Health